Heart Failure With Preserved Ejection Fraction Clinical Trial
— SPIRIT-HFOfficial title:
Spironolactone In The Treatment of Heart Failure- A Double-blind, Randomized, Placebo-controlled, Parallel Group Interventional Phase III Study to Determine Efficacy and Safety of Spironolactone on the Composite Endpoint of Recurrent Heart Failure Hospitalizations and Cardiovascular Death in Patients With Heart Failure With Mid-range or Preserved Ejection Fraction
The purpose of this study is to determine whether the treatment of patients with HFmrEF and HFpEF at high risk of cardiovascular events with the mineralocorticoid receptor antagonist (MRA) spironolactone reduces a composite of recurrent heart failure hospitalizations and cardiovascular mortality.
Status | Recruiting |
Enrollment | 1300 |
Est. completion date | December 31, 2024 |
Est. primary completion date | December 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 50 Years to 100 Years |
Eligibility | Inclusion Criteria: Patients eligible for inclusion in this study have to fulfill all of the following criteria: 1. Written informed consent. 2. Male or female, age = 50 years 3. Current symptoms of Heart Failure (NYHA = II) during VR 4. Symptom(s) of HF = 30 days prior to VR 5. HF Hospitalization or treatment with intravenous (IV) diuretics for worsening HF within 12 months prior to VR 6. Left ventricular ejection fraction = 40 % at screening measured by echocardiography and evidence of structural/ functional abnormalities (at least one of the following criteria): LAVI > 34 ml/m2// E/émean = 13// Mean e' (septal and lateral) < 9 cm/s 7. NT-proBNP > 300 pg/ml (SR) or > 900 pg/ml (AF) on the Visit 1 ECG; only if NT-proBNP is NOT available: BNP > 80/ 250 pg/ml (SR/AF) 8. Controlled systolic BP: defined as a target systolic BP < 140 mm Hg. Subjects with BP up to and including 160 mm Hg are eligible for enrollment if on 3 or more medications to control BP (Patients with uncontrolled BP should be considered for Re-Screening after optimization of antihypertensive therapy has been established) 9. Serum potassium < 5.0 mmol/L prior to randomization Exclusion Criteria: Patients fulfilling any of the following criteria are not eligible for inclusion in this study. The investigator may apply no additional exclusion criteria, in order to ensure that the study population will be representative of all eligible patients. 1. Hyperkalemia (potassium level = 5.5 mmol/L) within the past two weeks before VR 2. Hyponatraemia (sodium level < 135 mmol/L) prior to randomization 3. Severe renal dysfunction, defined as an estimated glomerular filtration rate of less than 30 mL/min/1.73m2) as calculated by the Modification in Diet in Renal Disease (MDRD) formula at Visit 1 or serum creatinine level = 1,8 mg/dl (> 160 µmol/ml) 4. History of anuria or acute renal failure (as defined by the RIFLE criteria for AKI; see Appendix XVIII.3) within the past two weeks before VRenal dysfunction, defined as an estimated glomerular filtration rate of less than 30 mL/min/1.73m2) as calculated by the Modification in Diet in Renal Disease (MDRD) formula at VScr/VR or serum creatinine level = 1,8 mg/dl (> 160 µmol/ml)History of anuria or acute renal failure (as defined by the RIFLE criteria for AKI; see Appendix XVIII.3) within the past two weeks prior to randomization 5. Acute coronary syndrome (including MI) and elective PCI within 30 days prior to VR. 6. Cardiac surgery, other major CV surgery, or urgent percutaneous coronary intervention (PCI) within the 3 months prior to VR 7. Current acute decompensated HF requiring augmented therapy with i.v. diuretics, i.v. vasodilators and/or i.v. inotropic drugs. Patients are eligible after initial stabilization. 8. Probable alternative diagnoses that in the opinion of the investigator could account for the patient's HF symptoms (i.e., dyspnea, fatigue) such as significant pulmonary disease (including primary pulmonary HTN), anemia or obesity. Specifically, patients with the following are not eligible for randomization: - Severe pulmonary disease including chronic obstructive pulmonary disease (COPD) or severe asthma bronchiale ( (ie requiring home oxygen, chronic nebulizer therapy, chronic oral steroid therapy) or - anemia (hemoglobin < 10 g/dL males and < 9.5 g/dL females), or - body mass index (BMI) > 40 kg/m2 9. Evidence of right sided HF in the absence of left-sided structural heart disease. 10. Specific etiologies such as infiltrative, genetic hypertrophic cardiomyopathy, pericardial constriction, sarcoidosis, amyloidosis and any other storage diseases. 11. Clinically significant congenital heart disease underlying heart failure. 12. Life-threatening or uncontrolled dysrhythmia, including symptomatic or sustained ventricular tachycardia and uncontrolled persistent or permanent atrial fibrillation (AF) or flutter (with a heart rate > 100 beats per minute (bpm), RACE II) during VR. If AF with HR > 100/min, the patient may be rescreened after treatment for rate control. 13. Presence of significant (i.e., more than moderate) valvular heart disease expected to lead to surgery during the trial in the investigators opinion. 14. Stroke, transient ischemic attack, carotid surgery or carotid angioplasty within the 3 months prior to VR. 15. Coronary or carotid artery disease or valvular heart disease likely to require surgical or percutaneous intervention within the 6 months after VR in the investigators opinion. 16. Patients with prior major organ transplant or intent to transplant (on transplant list) or with current ventricular assist device (VAD) therapy. 17. Evidence of hepatic disease as determined by any one of the following: SGOT (AST) or SGPT (ALT) values exceeding 3x the upper limit of normal (ULN), bilirubin >1.5 mg/dl at VR. 18. Evidence of present bilateral renal artery stenosis 19. Known intolerance or history of hypersensitivity to the active substance (Spironolactone) or to any of the excipients of the Investigational Medicinal Product (IMP) or placebo. 20. Present use of any aldosterone antagonist, potassium supplements or potassium sparing diuretics at the time of enrollment. (Consider stopping these potassium sparing drugs if clinically possible and upon discussion with the patient) 21. Required treatment with prohibited Co-medications according to the summary of product characteristics with the exception of ACE inhibitors or angiotensin receptor blockers (as described in the protocol in IV.2). , careful monitoring of plasma lithium and dose adjustment are required. 22. Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives before enrollment, whichever is longer. 23. Any condition that, in the opinion of the investigator may prevent the subject from adhering to the study protocol (e.g. history of non-compliance to medical regimens, patients who are considered potentially unreliable, patients with a history of addiction). 24. History or presence of any other disease (i.e. including malignancies) with a life expectancy of < 1 years. 25. History of non-compliance to medical regimens and patients who are considered potentially unreliable. 26. Subjects who are legally detained in an official institution. 27. Subjects who may be dependent on the sponsor, the investigator or the trial sites, have to be excluded from the trial. 28. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test. 29. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during study participation and until 2 months after the last dose off study drug. |
Country | Name | City | State |
---|---|---|---|
Austria | Medical University of Graz | Graz | |
Austria | Medical University Innsbruck | Innsbruck | |
Austria | Clinic Klagenfurt Wörthersee | Klagenfurt | |
Austria | University Hospital St. Pölten | Pölten | |
Austria | Medical University of Vienna | Vienna | |
France | Besançon University Hospital | Besançon | |
France | Centre Hospitalier de Beziers | Béziers | |
France | CHU Clermont-Ferrand | Clermont-Ferrand | |
France | Groupe Hospitalier de la Rochelle-Ré-Aunis | La Rochelle | |
France | CHU Grenoble Alpes Hopital Michallon | La Tronche | |
France | CHU Arnaud de villeneuve | Montpellier | |
France | CHRU Nancy Brabois | Nancy | |
France | CHU Haut Lévêque Cardiologie | Pessac | |
France | Hôpital Sainte Musse | Toulon | |
France | CHU Toulouse - Hôpital Rangueil | Toulouse | |
Germany | Kardiologische Praxis Dr. Wolfgang Jungmair | Bad Homburg | |
Germany | Kerckhoff Heart and Thorax Center | Bad Nauheim | |
Germany | Herz- und Diabeteszentrum NRW, Bad Oeynhausen | Bad Oeynhausen | |
Germany | Caritas-Klinik Maria Heimsuchung | Berlin | |
Germany | Charité University of Medicine (CVK) | Berlin | |
Germany | Charité University of Medicine Berlin, CCM | Berlin | |
Germany | Charité University of Medicine, CBF | Berlin | |
Germany | German Heart Center Berlin, Clinic for Internal Medicine - Cardiology | Berlin | |
Germany | Helios Klinikum Emil von Behring GmBH | Berlin | |
Germany | Klinische Forschung Berlin GbR | Berlin | |
Germany | Studienzentrum Rankestraße | Berlin | |
Germany | Städtisches Klinikum Brandenburg GmbH | Brandenburg an der Havel | |
Germany | Stiftung Bremer Herzen (BIHKF) | Bremen | |
Germany | Heart Center Dresden, Technical University of Dresden | Dresden | |
Germany | Zentrum für klinische Studien Dresden | Dresden | |
Germany | Zentrum für klinische Studien Südbrandenburg | Elsterwerda | |
Germany | University Hospital of Giessen | Gießen | |
Germany | University of Goettingen | Goettigen | |
Germany | University Medicine Greifswald | Greifswald | |
Germany | Universitätsklinikum Halle (Saale) | Halle (Saale) | |
Germany | University Heart Center Hamburg | Hamburg | |
Germany | University of Heidelberg | Heidelberg | |
Germany | University Hospital Jena | Jena | |
Germany | University Medical Center of Schleswig-Holstein, Campus Kiel | Kiel | |
Germany | Heart Center Leipzig-University Hospital | Leipzig | |
Germany | Universitätsklinikum Leipzig | Leipzig | |
Germany | University Hospital Schleswig-Holstein, University Heart Centre Lübeck | Lübeck | |
Germany | University Hospital Mainz | Mainz | |
Germany | University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University | Mannheim | |
Germany | Kliniken Maria Hilf GmbH | Mönchengladbach | |
Germany | German Heart Center Munich | Munich | |
Germany | University Hospital Klinikum rechts der Isar (TUM) | Munich | |
Germany | University Hospital Munich, Ludwig-Maximilians University | Munich | |
Germany | University Hospital rechts der Isar | Munich | |
Germany | Kardiologische Praxis Am Park Sanssoucci | Potsdam | |
Germany | Praxis Dr. Markus Knapp/Daniela Breuninger | Schwäbisch Hall | |
Germany | MVZ Schwering West GmbH | Schwerin | |
Germany | Universitätsklinikum Ulm | Ulm | |
Netherlands | Meander Medisch Centrum | Amersfoort | |
Netherlands | Ziekenhuis Amstelland | Amstelveen | |
Netherlands | OLVG locatie Oost | Amsterdam | |
Netherlands | Van Weel-Bethesda Ziekenhuis | Dirksland | |
Netherlands | St. Jansdal Ziekenhuis | Harderwijk | |
Netherlands | Elkerliek Ziekenhuis | Helmond | |
Netherlands | Gelre Ziekenhuizen | Zutphen | |
Serbia | Clinical Hospital Center B. Kosa | Belgrade | |
Serbia | Clinical Hospital Center Dr. Dragisa Misovic | Belgrade | |
Serbia | Clinical Hospital Center Zvezdara | Belgrade | |
Serbia | Dedinje Cardiovascular Institute | Belgrade | |
Serbia | Institute for Rehabilitation | Belgrade | |
Serbia | Nis Clinical Center | Niš | |
Serbia | Insitute of Cardiovascular Diseases of Vojvodina | Sremska Kamenica | |
Serbia | General Hospital Uzice | Užice | |
Serbia | General Hospital Vršac | Vršac |
Lead Sponsor | Collaborator |
---|---|
Charite University, Berlin, Germany | Coordinating Centre for Clinical Trials, Charité, Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), Echo Core Lab Berlin, Institute for Cardiovascular Computer-assisted Medicine, Charité, Ludwig-Maximilians - University of Munich, University Medicine Greifswald, University of Göttingen |
Austria, France, Germany, Netherlands, Serbia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Primary Objective: Cumulative number of primary composite events of cardiovascular (CV) death and total HF hospitalizations | Cumulative number of primary composite events of cardiovascular (CV) death and total (first and recurrent) HF hospitalizations in symptomatic HF patients (NYHA II-IV) with mid-range (LVEF 40- 49 %) or preserved (LVEF = 50 %) ejection fraction. | Time Frame: Total follow up time (up to 48 months) | |
Secondary | Secondary Objective: Comparison of spironolactone to placebo in reducing the rate of hospitalisations and deaths | To compare Spironolactone to placebo in reducing the recurrent rate of heart failure Hospitalizations [Time Frame: Follow-up time up to 48month.] To compare Spironolactone to placebo in reducing the rate of recurrent non-fatal hospitalizations from cardiovascular (CV) cause (i.e. hospitalization for non-fatal MI, non-fatal stroke, or the management of heart failure, whichever occurred first) [Time Frame: Total follow up time (up to 48 months)]. To compare Spironolactone to placebo in reducing the recurrent rate of hospitalizations from any cause [Time Frame: Total follow up time (up to 48 months)]. To compare Spironolactone to placebo in reducing the rate of death from cardiovascular (CV) cause [Time Frame: Total follow up time (up to 48 months)]. To compare Spironolactone to placebo in reducing the rate of death from any cause [Time Frame: Total follow up time (up to 48 months)]. |
Time Frame: Total follow up time (up to 48 months) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Suspended |
NCT05839730 -
Fast Induced Remodeling in Heart Failure With Preserved Ejection Fraction
|
N/A | |
Recruiting |
NCT05095688 -
Relationship Between Adipose Tissue Distribution and Arterial Stiffness in HFpEF
|
||
Recruiting |
NCT06379152 -
Effect of Bilirubin on Prognosis in Heart Failure With Preserved Ejection Fraction
|
||
Recruiting |
NCT05676684 -
Dapagliflozin, Spironolactone or Both for HFpEF
|
Phase 2/Phase 3 | |
Recruiting |
NCT04153136 -
Effects of Sacubitril/Valsartan on Subclinical Heart Failure in HIV (The ENCHANTMENT HIV Study)
|
Phase 2 | |
Recruiting |
NCT05715697 -
Renal Denervation in Patients With Chronic Heart Failure With Preserved Ejection Fraction
|
N/A | |
Recruiting |
NCT06114498 -
Hospital Register of Decompensated Heart Failure With Preserved Ejection Fraction
|
||
Recruiting |
NCT04745013 -
PeRsonalIzed remOtely Guided Preventive exeRcIse Therapy for a healThY Heart
|
N/A | |
Completed |
NCT05586828 -
A Single-center Retrospective Cohort Study to Explore the Prognostic Significance of CONUT in Elderly CAD Patients With HFpEFand Compare CONUT With Other Objective Nutritional Indices.
|
||
Completed |
NCT05126836 -
Cilostazol for HFpEF
|
Phase 2 | |
Recruiting |
NCT04594499 -
The Relationship Between Pericardial Fat Thickness and Arterial Stiffness in HFpEF Patients
|
||
Active, not recruiting |
NCT05204238 -
Follow Up of acuTe Heart failUre: a pRospective Echocardiographic and Clinical Study (FUTURE)
|
||
Completed |
NCT04535726 -
The Relationship Between Blood Pressure and Arterial Stiffness in HFpEF Patients With Different Levels of Obesity
|
||
Recruiting |
NCT03550235 -
Exploration of Dyspnea at Non-high Brain Natriuretic Peptide (BNP)
|
||
Completed |
NCT04633460 -
Acute Effects of Exogenous Ketone Ester Administration in Heart Failure
|
Phase 2 | |
Completed |
NCT06228807 -
Clinical Characteristics and Predictors of Adverse Outcomes in HFpEF
|
||
Active, not recruiting |
NCT05284617 -
Exploratory Ph 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, PD, & PK of HU6 for Subjects With Obese HFpEF
|
Phase 2 | |
Recruiting |
NCT05562063 -
Sotagliflozin in Heart Failure With Preserved Ejection Fraction (HFpEF) Patients
|
Phase 4 | |
Recruiting |
NCT06027307 -
Enavogliflozin Outcome Trial in Functional Tricuspid Regurgitation
|
Phase 3 | |
Recruiting |
NCT05582044 -
Exercise Lower-body Negative Pressure in Heart Failure With Preserved Ejection Fraction
|
N/A |